Wickenden AD - Search Results

1

Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.

Wickenden AD, Zou A, Wagoner PK, Jegla T. Wickenden AD, et al. Br J Pharmacol. 2001 Jan;132(2):381-4. doi: 10.1038/sj.bjp.0703861. Br J Pharmacol. 2001. PMID: 11159685 Free PMC article.

2

Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.

Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Wickenden AD, et al. Mol Pharmacol. 2000 Sep;58(3):591-600. doi: 10.1124/mol.58.3.591. Mol Pharmacol. 2000. PMID: 10953053

3

N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, Roeloffs R, McNaughton-Smith G, Rigdon GC. Wickenden AD, et al. Mol Pharmacol. 2008 Mar;73(3):977-86. doi: 10.1124/mol.107.043216. Epub 2007 Dec 18. Mol Pharmacol. 2008. PMID: 18089837

4

Distribution and functional properties of human KCNH8 (Elk1) potassium channels.

Zou A, Lin Z, Humble M, Creech CD, Wagoner PK, Krafte D, Jegla TJ, Wickenden AD. Zou A, et al. Among authors: wickenden ad. Am J Physiol Cell Physiol. 2003 Dec;285(6):C1356-66. doi: 10.1152/ajpcell.00179.2003. Epub 2003 Jul 30. Am J Physiol Cell Physiol. 2003. PMID: 12890647 Free article.

5

Electrophysiological analysis of heterologously expressed Kv and SK/IK potassium channels.

Castle NA, Wickenden AD, Zou A. Castle NA, et al. Among authors: wickenden ad. Curr Protoc Pharmacol. 2003 May;Chapter 11:Unit11.5. doi: 10.1002/0471141755.ph1105s20. Curr Protoc Pharmacol. 2003. PMID: 21956802

6

Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4.

Brenner R, Jegla TJ, Wickenden A, Liu Y, Aldrich RW. Brenner R, et al. J Biol Chem. 2000 Mar 3;275(9):6453-61. doi: 10.1074/jbc.275.9.6453. J Biol Chem. 2000. PMID: 10692449 Free article.

7

Regional contributions of Kv1.4, Kv4.2, and Kv4.3 to transient outward K+ current in rat ventricle.

Wickenden AD, Jegla TJ, Kaprielian R, Backx PH. Wickenden AD, et al. Am J Physiol. 1999 May;276(5):H1599-607. doi: 10.1152/ajpheart.1999.276.5.H1599. Am J Physiol. 1999. PMID: 10330244

8

Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.

Gross MF, Castle NA, Zou A, Wickenden AD, Yu W, Spear KL. Gross MF, et al. Among authors: wickenden ad. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3063-6. doi: 10.1016/j.bmcl.2009.04.002. Epub 2009 Apr 8. Bioorg Med Chem Lett. 2009. PMID: 19398199

9

K(+) channels as therapeutic drug targets.

Wickenden A. Wickenden A. Pharmacol Ther. 2002 Apr-May;94(1-2):157-82. doi: 10.1016/s0163-7258(02)00201-2. Pharmacol Ther. 2002. PMID: 12191600 Review.

10

In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.

Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J, McNamara JO, Ghodadra N, Rigdon GC. Roeloffs R, et al. Among authors: wickenden ad. J Pharmacol Exp Ther. 2008 Sep;326(3):818-28. doi: 10.1124/jpet.108.137794. Epub 2008 Jun 24. J Pharmacol Exp Ther. 2008. PMID: 18577704

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page